Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study

被引：3
|
作者：
Miura, Ryosuke [1 ]
Okada, Kouji [1 ,2 ]
机构：
[1] Tohoku Med & Pharmaceut Univ Hosp, Dept Pharm, 1-12-1 Fukumuro,Miyagino ku, Sendai, Miyagi 9838512, Japan
[2] Tohoku Med & Pharmaceut Univ, Div Clin Pharmaceut & Pharm Practice, 1-12-1 Fukumuro,Miyagino ku, Sendai, Miyagi 9838512, Japan
来源：
HYPERTENSION RESEARCH | 2023年 / 46卷 / 12期
关键词：
Angiotensin-converting enzyme inhibitor; Angiotensin II receptor blocker; COVID-19; Hypertension; Prescriptions; BLOOD-PRESSURE CONTROL; MEDICATION USE; THERAPY; HYPERTENSION; HEALTH;
D O I：
10.1038/s41440-023-01373-0
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
We surveyed changes in angiotensin-converting enzyme inhibitor (ACEIs) and angiotensin II receptor blocker (ARBs) prescription trends during the coronavirus disease 2019 (COVID-19) pandemic in Japan. Data of 1,605,708 outpatients with hypertension were extracted from the Medical Data Vision database. Trends for prescription of ACEIs and ARBs were assessed by analyzing the proportion of these prescriptions in each month, between April 2018 and November 2020. The proportion of ARBs prescriptions changed significantly in trend between the peri-pandemic and pre-pandemic periods (-0.05%/month, P = 0.012). In contrast, the proportion of ACEIs prescriptions did not change significantly in trend in the peri-pandemic period (0.01%/month, P = 0.189). There was no suggestion that the prescribing of ACEIs and ARBs was affected by the COVID-19 pandemic.
引用
收藏
页码：2593 / 2602
页数：10
相关论文
共 50 条
  • [1] Prescription of renin-angiotensin system inhibitors in Japan during the COVID-19 pandemic: interrupted time series study
    Ryosuke Miura
    Kouji Okada
    Hypertension Research, 2023, 46 : 2593 - 2602
  • [2] Renin-Angiotensin System Inhibitors and the COVID-19 Pandemic
    Muchaili, Lweendo
    Mweene, Bislom C.
    Masenga, Sepiso K.
    AMERICAN JOURNAL OF HYPERTENSION, 2023, 36 (07) : 360 - 362
  • [3] RENIN-ANGIOTENSIN SYSTEM INHIBITORS IN MANAGEMENT OF HYPERTENSION DURING THE COVID-19 PANDEMIC
    Dworakowska, D.
    Grossman, A. B.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2020, 71 (02): : 1 - 6
  • [4] Discontinuation of Renin-Angiotensin System Inhibitors During the Early Stage of the COVID-19 Pandemic
    Muntner, Paul
    Foti, Kathryn
    Wang, Zhixin
    Alanaeme, Chibuike J.
    Choi, Eunhee
    Bress, Adam P.
    Shimbo, Daichi
    Kronish, Ian
    AMERICAN JOURNAL OF HYPERTENSION, 2023, 36 (07) : 404 - 410
  • [5] Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic
    South, Andrew M.
    Tomlinson, Laurie
    Edmonston, Daniel
    Hiremath, Swapnil
    Sparks, Matthew A.
    NATURE REVIEWS NEPHROLOGY, 2020, 16 (06) : 305 - 307
  • [6] Renin-angiotensin system blockade in the COVID-19 pandemic
    Cohen, Jordana B.
    South, Andrew M.
    Shaltout, Hossam A.
    Sinclair, Matthew R.
    Sparks, Matthew A.
    CLINICAL KIDNEY JOURNAL, 2021, 14 : 48 - 59
  • [7] Renin-angiotensin system at the heart of COVID-19 pandemic
    Alifano, Marco
    Alifano, Pietro
    Forgez, Patricia
    Iannelli, Antonio
    BIOCHIMIE, 2020, 174 : 30 - 33
  • [8] Renin-angiotensin system inhibitors in the COVID-19 pandemic: consequences of antihypertensive drugs
    Ruilope, Luis M.
    Tamargo, Juan
    Ruiz-Hurtado, Gema
    EUROPEAN HEART JOURNAL, 2020, 41 (22) : 2067 - 2069
  • [9] Evidence That Renin-Angiotensin System Inhibitors Should Not Be Discontinued Due to the COVID-19 Pandemic
    Carey, Robert M.
    Wang, Ji-Guang
    HYPERTENSION, 2020, 76 (01) : 42 - 43
  • [10] Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19
    Lee, Matthew M. Y.
    McMurray, John J. V.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (14): : 1155 - 1156
12345